SCHEMBL6789705

SCHEMBL6789705

Clc1ccc(Nc2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCOC3)cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.35
HTR2A P28223 2/20 0.35
HTR2B P41595 2/20 0.35
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
OPRD1 P41143 1/20 0.32
GAA P10253 1/20 0.31
CCR2 P41597 1/20 0.31
KCNH2 Q12809 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
MCL1 Q07820 1/20 0.31
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491977 0.92 HTR2C (0.34) HTR2CHTR2AHTR2B
SCHEMBL6499928 0.89 HTR2C (0.41) HTR2CHTR2AHTR2BMAPTHTT
SCHEMBL6497366 0.87 HTR2C (0.34) HTR2CHTR2AHTR2B
SCHEMBL6785048 0.87 HTR2C (0.39) HTR2CHTR2AHTR2B
SCHEMBL6492094 0.87 HTR2C (0.36) HTR2CHTR2AHTR2BMAPT
SCHEMBL6491699 0.86 HTR2C (0.39) HTR2CHTR2AHTR2BPOLBGAA
SCHEMBL6785531 0.85 HTR2C (0.34) HTR2CHTR2AHTR2B
SCHEMBL6490500 0.85 JAK3 (0.34) HTR2CHTR2AHTR2BLMNA
SCHEMBL6492068 0.85 HTR2C (0.34) HTR2CHTR2AHTR2B
SCHEMBL6493532 0.84 HTR2C (0.38) HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-09-23 US disclosed
US-6699852-B2 ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-02 US disclosed
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.